Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2005

View Archived Issues

Data on the survival effects of seocalcitol in advanced HCC

Remofovir reported to reduce viral load of patients with chronic hepatitis B

LB-80380 shows promise in the treatment of lamivudine-resistant hepatitis B

Idenix presents new data on drugs for chronic hepatitis

Good analgesic efficacy found with lamotrigine plus sertraline in neuropathic pain

Bioaccelerate Holdings and Symbollon enter agreement for IoGen

Cloretazine studied in phase I trial for pediatric brain tumors

SPI-153 enters phase II trial for BPH

Response submitted to FDA for Glumetza NDA

Priority review for SomatoKine

Orchid BioSciences seeks approval to change name to Orchid Cellmark

YM BioSciences to acquire Delex Therapeutics

Lilly licenses therapeutic proteins from Xencor

SCOLR Pharma adds three drug targets to CDT drug development program

Evotec OAI extends discovery chemistry agreement with Roche

Novel analgesic drugs presented in recent patent literature

Chemokine CCR5 modulators and their use as anti-HIV agents claimed by ViroChem and AstraZeneca

Acusphere amends phase III plans for AI-700

SDF-1 antagonist significantly reduces osteosarcoma metastases in animal model

Intranasal Technology inlicenses Aegis' Intravail drug delivery technology

ZSTK-474: a novel PI3K inhibitor with a promising preclinical profile

New indication approved for Hyzaar

Kos and Barr sign agreements to settle Niaspan patent litigation

Avastin improves progression-free survival in phase III breast cancer study

Albuferon safe and active in phase II trial in hepatitis C patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...